Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.
Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabrò F, Tema G, Leonardo C, Flammia RS, Tuderti G, Anceschi U, Brassetti A, Giacinti S, Guaglianone S, Ghahhari J, Schips L, Tubaro A, Gallucci M, Simone G. Ferriero M, et al. Among authors: calabro f. World J Urol. 2020 Jul;38(7):1757-1764. doi: 10.1007/s00345-019-02974-6. Epub 2019 Oct 12. World J Urol. 2020. PMID: 31605196
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study.
Gacci M, Marchioni M, DE Francesco P, Natoli C, Calabrò F, Losanno T, Gianmartin C, Serni S, Doni L, DE Nunzio C, DE Tursi M, Valeriani M, Giacinti S, Álvarez-Maestro M, Scarcia M, Ludovico GM, Del Bene G, Simone G, Ferriero M, Tuderti G, Bove P, Laudisi A, Carrieri G, Cormio L, Verze P, LA Rocca R, Falsaperla M, Frantellizzi V, Greco F, DI Nicola M, Schips L, Cindolo L. Gacci M, et al. Among authors: calabro f. Minerva Urol Nephrol. 2021 Aug;73(4):489-497. doi: 10.23736/S2724-6051.20.03723-6. Epub 2020 Aug 4. Minerva Urol Nephrol. 2021. PMID: 32748613 Free article.
Stratifying the Risk of Disease Progression among Surgically Treated Muscle-Invasive Bladder Cancer Eligible for Adjuvant Nivolumab.
Flammia RS, Tuderti G, Bologna E, Minore A, Proietti F, Licari LC, Mastroianni R, Bove AM, Anceschi U, Brassetti A, Ferriero MC, Guaglianone S, Chiacchio G, Calabrò F, Leonardo C, Simone G. Flammia RS, et al. Among authors: calabro f. J Clin Med. 2024 Sep 14;13(18):5466. doi: 10.3390/jcm13185466. J Clin Med. 2024. PMID: 39336951 Free PMC article.
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.
Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN. Del Bene G, et al. Among authors: calabro f. Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018. Front Oncol. 2018. PMID: 30510914 Free PMC article.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Adjuvant chemotherapy for bladder cancer.
Sternberg CN, Calabró F. Sternberg CN, et al. Among authors: calabro f. Expert Rev Anticancer Ther. 2005 Dec;5(6):987-92. doi: 10.1586/14737140.5.6.987. Expert Rev Anticancer Ther. 2005. PMID: 16336089 Review.
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M. Sternberg CN, et al. Among authors: calabro f. J Clin Oncol. 2009 Nov 10;27(32):5431-8. doi: 10.1200/JCO.2008.20.1228. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805692 Clinical Trial.
Chemotherapy for Muscle-Invasive Bladder Cancer.
Trenta P, Calabrò F, Cerbone L, Sternberg CN. Trenta P, et al. Among authors: calabro f. Curr Treat Options Oncol. 2016 Jan;17(1):6. doi: 10.1007/s11864-015-0376-y. Curr Treat Options Oncol. 2016. PMID: 26810055 Review.
298 results